August 26, 2025 — Leads & Copy — Marker Therapeutics, Inc. (Nasdaq: MRKR) has announced an update on its Phase 1 APOLLO study, revealing promising results for MT-601 in treating relapsed B cell lymphoma. The study showed a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients, with 50% achieving complete response (CR). The treatment also demonstrated a favorable safety profile, with no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) observed.
The dose expansion phase will assess MT-601 at a pre-specified maximum dose in patients with Diffuse Large B Cell Lymphoma (DLBCL) who have relapsed after or are ineligible for CAR-T cell therapy. A total of 24 B-cell lymphoma patients were treated with MT-601 across seven U.S. clinical sites.
According to Juan Vera, M.D., President and CEO of Marker Therapeutics, the data underscores the potential of MT-601 in heavily pre-treated lymphoma patients, offering new hope for those who have exhausted multiple lines of treatment.
Contact:
Marker Therapeutics, Inc.
+1 (713) 400-6400
investor.relations@markertherapeutics.com
Source: Marker Therapeutics, Inc.
